Targets › COLLAGEN
1 program from 1 company in 2 trials: 2 Phase 3; Ophthalmology; next expected readout Nov 2028.
Open in Phaseline: the race on COLLAGEN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Woolfson Eye Institute | Epi-ON corneal cross-linking Riboflavin (vitamin B2) photosensitization with UVA light exposure to induce corneal colla | COLLAGEN | Phase 3 | Keratoconus; Down Syndrome (DS) | Nov 2028 |
Keratoconus (1) Down Syndrome (DS) (1)
–
Woolfson Eye Institute (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.